Express Pharma

Biocon’s partner Mylan receives favourable ruling from US PTAB on Sanofi’s four device patents for Lantus SoloSTAR

Reportedly, the PTAB also found Sanofi’s proposed amended claims for the ‘486 and ‘844 patents unpatentable.

0 698

Biocon announced that the US Patent and Trademark Appeal Board (PTAB) has ruled in favour of Mylan, Biocon’s partner in inter partes review (IPR) proceedings finding all challenged claims of Sanofi’s Lantus SoloSTAR device patents, US Patent Nos. 8,603,044, 8,992,486, and 9,526,844 unpatentable. The PTAB found three claims of the 9,604,008 patent unpatentable, and two claims to be patentable. However, Mylan and Biocon have previously obtained a covenant not to sue from Sanofi on the ‘008 patent and therefore this ruling does not impact Biocon and Mylan’s ability to commercialise Semglee (Insulin Glargine) upon final approval from the US Food and Drug Administration. The PTAB also found Sanofi’s proposed amended claims for the ‘486 and ‘844 patents unpatentable.

Dr Christiane Hamacher, CEO & Managing Director, Biocon Biologics said, “Our partner’s New Drug Application (NDA) for Semglee is under active review by the US FDA and this favourable ruling further clears the path for the anticipated launch of our Glargine in the US in mid-CY20.”

Last month, the PTAB  held the sole challenged claim of another Lantus SoloSTAR device patent as unpatentable for US Patent No. 8,679,069, and in March, Mylan and Biocon announced that the US District Court of New Jersey found the asserted claims of the ‘844 patent not infringed by Mylan’s Insulin Glargine product and invalid for lack of written description. Sanofi’s formulation patents (U.S. Patent Nos. 7,476,652 and 7,713,930) were previously affirmed to be invalid by the Federal Circuit by a non-appealable decision.

Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes for the control of high blood sugar. Our partner, Mylan’s 505(b)(2) New Drug Application (NDA) is under active review by the U.S. Food and Drug Administration.

Sanofi sells the product in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR).

- Advertisement -